US intelligence finds no proof tying 'Havana syndrome' health issues to foreign actors, but 2 agencies say it's possible.
Cholesterol levels are something that many people tend to struggle with, but with the right information and lifestyle changes ...
Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...
El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...
The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback